XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc. (Nasdaq: XYN) is a clinical-stage biopharmaceutical company focused on oncology drug development that entered the public markets through a SPAC-related transaction. The company filed an 8-K with the Securities and Exchange Commission on May 2, 2019, bearing accession number 0001213900-19-007632, disclosing a material corporate event consistent with its post-combination reporting obligations. Xynomic operates in the pharmaceutical and life sciences sector, with its pipeline concentrated on cancer therapeutics. For complete filing histories, deal timelines, and real-time data on Xynomic Pharmaceuticals Holdings and thousands of other SPAC transactions, sign up for full access at SpacDesk.